Basal Cell and Squamous Cell Skin Cancers: NCCN Guidelines® Updates Based on Risk Status
While the prognosis for patients with squamous and basal cell skin cancer is generally good, current treatment recommendations are limited by the risk status classifications and associated available treatment options. There are subsets of patients who are prone to recurrence or regional and distant metastasis. Awareness of these disease features is crucial to identifying such patients and performing the appropriate treatment, especially as new regimens become available.
NCCN Guidelines® Insights - Merkel Cell Carcinoma, Version 1.2024
These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled “Clinical N0 Disease, Locally Advanced MCC.” This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term “nonsurgical” by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
Management of Patients with Aggressive Non-Melanoma Skin Cancers
Even though the prognosis for patients with non-melanoma skin cancer is generally good, there are subsets of patients who are prone to recurrence or regional and distant metastasis. Awareness of aggressive disease features is, thus, crucial to identify such patients. It is also important for clinicians to stay up-to-date on the current treatment options for these patients.
NCCN Guidelines® Insights - Squamous Cell Skin Cancer, Version 1.2022
These NCCN Guidelines Insights focus on the introduction of a new surgical recommendation terminology (peripheral and deep en face margin assessment), as well as recent updates on topical prophylaxis, immunotherapy for regional and metastatic disease, and radiation therapy.
Management of a Patient With Advanced BRAF-Mutant Melanoma

Given the recent expansion of treatment options in advanced melanoma, oncologists now have the opportunity to choose among multiple effective and fairly well-tolerated treatment options.

Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma

Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimal management of Merkel cell carcinoma.

Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma

Join Jeffrey M. Farma, MD (Surgeon) and Anthony J. Olszanski, MD, RPh (Medical Oncologist) as they present their multidisciplinary expertise on a range of cases pertaining to melanoma.

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Melanoma

Join Jeffrey M. Farma, MD (Surgeon) and Anthony J. Olszanski, MD, RPh (Medical Oncologist) as they present their multidisciplinary expertise on a range of cases pertaining to melanoma.

NCCN Guidelines® Insights - Melanoma, Version 2.2013

The NCCN Guidelines for Melanoma provide multidisciplinary recommendations on the clinical management of patients with melanoma. This NCCN Guidelines Insights report highlights notable recent updates.

Recorded Presentations from the NCCN 2012 Congress Webinar Series: Skin Cancers™: Management of Basal Cell and Squamous Cell Carcinoma of the Skin

This archived webinar series is designed to provide an in-depth analysis of the evidence and clinical decision-making that led to the development of the NCCN Guidelines® for Melanoma and Non-Melanoma Skin Cancers.

Pages

Subscribe to RSS - Skin Cancers